Ross Muken
Stock Analyst at Evercore ISI Group
(2.01)
# 2,956
Out of 4,944 analysts
46
Total ratings
56%
Success rate
0.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ross Muken
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintains: Outperform | $180 → $190 | $155.00 | +22.58% | 8 | Aug 8, 2025 | |
| HSIC Henry Schein | Maintains: In-Line | $78 → $70 | $68.99 | +1.46% | 10 | Aug 6, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $170 → $240 | $176.29 | +36.14% | 9 | Jul 25, 2025 | |
| A Agilent Technologies | Maintains: In-Line | $126 → $130 | $120.29 | +8.07% | 11 | Jul 2, 2024 | |
| QGEN Qiagen | Downgrades: In-Line | n/a | $49.23 | - | 2 | Jul 16, 2019 | |
| CAH Cardinal Health | Initiates: In-Line | $67 | $148.12 | -54.77% | 2 | Jan 5, 2018 | |
| ILMN Illumina | Initiates: Outperform | $250 | $101.11 | +147.26% | 2 | Jan 4, 2018 | |
| TMO Thermo Fisher Scientific | Initiates: Outperform | $220 | $484.79 | -54.62% | 1 | Jan 4, 2018 | |
| MBLY Mobileye Global | Downgrades: In-Line | n/a | $14.25 | - | 1 | Mar 13, 2017 |
Charles River Laboratories International
Aug 8, 2025
Maintains: Outperform
Price Target: $180 → $190
Current: $155.00
Upside: +22.58%
Henry Schein
Aug 6, 2025
Maintains: In-Line
Price Target: $78 → $70
Current: $68.99
Upside: +1.46%
ICON Public Limited Company
Jul 25, 2025
Maintains: Outperform
Price Target: $170 → $240
Current: $176.29
Upside: +36.14%
Agilent Technologies
Jul 2, 2024
Maintains: In-Line
Price Target: $126 → $130
Current: $120.29
Upside: +8.07%
Qiagen
Jul 16, 2019
Downgrades: In-Line
Price Target: n/a
Current: $49.23
Upside: -
Cardinal Health
Jan 5, 2018
Initiates: In-Line
Price Target: $67
Current: $148.12
Upside: -54.77%
Illumina
Jan 4, 2018
Initiates: Outperform
Price Target: $250
Current: $101.11
Upside: +147.26%
Thermo Fisher Scientific
Jan 4, 2018
Initiates: Outperform
Price Target: $220
Current: $484.79
Upside: -54.62%
Mobileye Global
Mar 13, 2017
Downgrades: In-Line
Price Target: n/a
Current: $14.25
Upside: -